MIR4 Releases Updates With Exciting New Battle Content
5.10.2021 08:00:00 EEST | Business Wire | Press release
Wemade Co., Ltd.’s masterpiece mobile MMORPG, MIR4 released new battle content, 'Attack of the Living Wraiths', on October 5. Attack of the Living Wraiths will be held every Thursday from 10:00 to 11:00 pm local server time, throughout the fourth floor in Bicheon, Snake, and Redmoon Hidden Valleys.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004006051/en/
Wemade Co., Ltd.’s masterpiece mobile MMORPG, MIR4 released new battle content, 'Attack of the Living Wraiths'. Once Attack of the Living Wraiths begin, players will be able to fight fiercely against named monsters, semi-bosses, and boss monsters, while acquiring treasure chests. Attack of the Living Wraiths will be held every Thursday from 10:00 to 11:00 pm local server time, throughout the fourth floor in Bicheon, Snake, and Redmoon Hidden Valleys. In addition, a new Raid (Wailing Dead Mine - level 115) as well as a new Boss Raid (Nefariox King - level 105) is included with the update. Future update plans include Class Change and release of a new character - Arbalist, expected to be released in November. (Graphic: Business Wire)
"Once Attack of the Living Wraiths begin, players will be able to fight fiercely against named monsters, semi-bosses, and boss monsters, while acquiring treasure chests with rich rewards such as Epic-grade Dragon Materials, Mystic Enhancement Stones, and Blue Dragon statues,” says Wemade. "Those who defeat named monsters will have a chance to summon semi-boss monsters, and by overcoming semi-boss monsters, a boss monster may appear by chance."
In addition to Attack of the Living Wraiths content, a new Raid (Wailing Dead Mine - level 115) as well as a new Boss Raid (Nefariox King - level 105) is included with the update. Players who defeat [Nefariox King: Boss Raid] will become eligible to purchase a new mount - 'Hell Horse'.
Future update plans include Class Change and release of a new character - Arbalist, expected to be released in November. Class change, unlocked when the character reaches level 50, allows players to switch characters between: Warrior, Sorcerer, Taoist, Lancer, and Arbalist, while maintaining the character’s physical constitution, inner strength, and solitude training. Arbalist, the only long-distance physical attack type character in MIR4, has extreme destructive power through the use of improved-crossbow and possesses excellent survivability through martial arts prowess.
From my battle to our war! Visit the official website for more information about MIR4.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211004006051/en/
Contact information
Press contact:
Wemade Co., Ltd. (112040: KOSDAQ)
Yeonghyun Lee, PR Manager
yeonghyun@wemade.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom